DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
i  
A Randomized, Double -Blind, Placebo Controlled, Phase 2 
Study  to Assess Treatment of Gardnerella Vaginalis Vaginal 
Colonization with Amoxicillin  
DMID Protocol Number:  16-0073  
 
DMID Funding Mechanism:  HHSN2722013000121; HHSN272000011  
Principal Investigator:  [INVESTIGATOR_805066], MD  
DMID Protocol Champi[INVESTIGATOR_2394]:  Delmyra Turpin , RN, MPH, CCRP  
DMID Medical Monitor:  Mohamed Elsafy, M.D  
DMID Scientific Lead:  Carolyn Deal, Ph.D.  
Version Number:   6.0 
23 May 2019  
 
 
  
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
ii STATEMENT OF COMPLIA NCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by [CONTACT_14504]:  
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies 
(45 CFR Part 46; 21 CFR  Part 50, 21 CFR Part 56, and 21 CFR Part 312 ) 
• ICH E6; 62 Federal Register [ZIP_CODE] (1997)  
• NIH Clinical Terms of Award  
 
All key personnel (all individuals responsible for the design and conduct of this study) have 
completed Human Subjects Protection Training . 
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
iii SIGNATURE [CONTACT_19841], and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines.  
 
Principal Investigator  [INVESTIGATOR_651084] : 
 
 Date:   
Jane Schwebke, MD  
University of Alabama at Birmingham  
 
 
Site Investigator:  
   
 Date:   
Candice McNeil , MD, MPH  
Wake Forest University Health Sciences    
 
DMID Protocol [ADDRESS_1111405] of Abbreviations  vii 
Protocol Summary  ix 
1 Key Roles  1 
2 Background Information and Scientific Rationale  3 
 Background Information  ................................ ................................ ..........................  3 
 Rationale  ................................ ................................ ................................ ................  3 
 Potential Risks and Benefits  ................................ ................................ ...................  4 
2.3.1  Potential Risks  ................................ ................................ ............................  4 
2.3.2  Known Potential Benefits ................................ ................................ .............  4 
3 Objectives  5 
 Study Objectives  ................................ ................................ ................................ ..... 5 
3.1.1  Primary objective:  ................................ ................................ ........................  5 
3.1.2  Secondary objective:  ................................ ................................ ...................  5 
3.1.3  Exploratory objective:  ................................ ................................ ..................  5 
 Study Outcome Measures  ................................ ................................ ......................  5 
3.2.1  Primary Outcome Measures  ................................ ................................ ........  5 
3.2.2  Secondary Outcome Measures  ................................ ................................ ... 5 
3.2.3  Exploratory Outcome Measures  ................................ ................................ .. 5 
4 Study Design  6 
5 Study Enrollment and Withdrawal  8 
 Participant Inclusion Criteria  ................................ ................................ ...................  8 
 Participant Exclusion Criteria  ................................ ................................ ..................  9 
 Treatment Assignment Procedures  ................................ ................................ ....... 10 
5.3.1  Randomization Procedures  ................................ ................................ ....... 10 
5.3.2  Masking Procedures  ................................ ................................ ..................  10 
5.3.3  Reasons for Withdrawal  ................................ ................................ ............  11 
5.3.4  Handling of Withdrawals  ................................ ................................ ............  11 
5.3.5  Termination of Study  ................................ ................................ .................  12 
6 Study Intervention/Investigational Product  [ADDRESS_1111406] Storage and Stability  ................................ ................................ .... 14 
 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product  ................................ ................................ ................................ .................  14 
6.2.1  Dosage  ................................ ................................ ................................ ...... 14 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
v 6.2.2  Preparation  ................................ ................................ ...............................  14 
6.2.3  Administration  ................................ ................................ ...........................  15 
 Accountability Procedures for the Study Intervention/Investigational Product(s)  ... 15 
 Assessment of Participant Compliance with Study Intervention/Investigational 
Product  ................................ ................................ ................................ .................  15 
 Concomitant Medications/Treatments  ................................ ................................ ... 16 
7 Study Schedule  17 
 Visit 0 (Day -14 to -7) Screening  ................................ ................................ ...........  17 
 Visit 1 (Day 1) Enrollment  ................................ ................................ .....................  18 
 Visit 2 (Day 15 [Window: Days 15 -21]) Follow -up (ToC)  ................................ ....... 19 
 Early Termination Visit  ................................ ................................ ..........................  19 
 Unscheduled Visit  ................................ ................................ ................................ . 20 
8 Study Procedures/Evaluations  21 
 Clinical Evaluations  ................................ ................................ ...............................  21 
 Laboratory Evaluations  ................................ ................................ .........................  22 
8.2.1  Clinical Laboratory Evaluations  ................................ ................................ . 22 
8.2.2  Special Assays or Procedures  ................................ ................................ ... 23 
8.2.3  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  ................................ ........  23 
9 Assessment of Safety  24 
 Specification of Safety Parameters  ................................ ................................ ....... 24 
 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ................................ ................................ ................................ ...........  24 
9.2.1  Adverse Events  ................................ ................................ .........................  24 
9.2.2  Serious Adverse Events  ................................ ................................ ............  26 
9.2.3  Procedures to be Followed in the Event of Abnormal Clinical Findings  ..... 26 
 Reporting Procedures  ................................ ................................ ...........................  27 
9.3.1  Serious Adverse Events  ................................ ................................ ............  27 
9.3.2  Regulatory Reporting for Studies Not Conducted Under 
DMID -Sponsored IND  ................................ ................................ ...............  27 
9.3.3  Reporting of  Pregnancy  ................................ ................................ .............  28 
 Type and Duration of Follow -up of Participants after Adverse Events  ...................  28 
 Halting Rules  ................................ ................................ ................................ ........  29 
 Safety Oversight ( ISM plus DSMB)  ................................ ................................ ....... 29 
10 Clinical Monitoring  31 
 Site Monitoring Plan  ................................ ................................ ..............................  31 
11 Statistical Considerations  32 
 Study Hypotheses  ................................ ................................ ................................ . 32 
 Sample Size Considerations  ................................ ................................ .................  32 
 Planned Interim Analyses  ................................ ................................ .....................  32 
11.3.1  Safety Review  ................................ ................................ ...........................  32 
11.3.2  Efficacy Review  ................................ ................................ .........................  33 
 Final Analysis Plan  ................................ ................................ ...............................  33 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
vi 11.4.1  Analysis Populations  ................................ ................................ .................  33 
11.4.2  Baseline Characteristics  ................................ ................................ ............  34 
11.4.3  Safety Analysis Plan  ................................ ................................ ..................  34 
11.4.4  Efficacy Analysis Plan  ................................ ................................ ...............  34 
12 Source Documents and Access to Source Data/Documents  36 
13 Quality Control and Quality Assurance  37 
14 Ethics/Protection of Human Subjects  [ADDRESS_1111407]  ................................ ................................ ....................  38 
 Informed Consent Process  ................................ ................................ ...................  38 
 Exclusion of Women, Minorities, and Children (Special Populations)  ....................  [ADDRESS_1111408] Keepi[INVESTIGATOR_007]  42 
 Data Management Responsibilities  ................................ ................................ ....... 42 
 Data Capture Methods  ................................ ................................ ..........................  42 
 Types of Data  ................................ ................................ ................................ ....... 43 
 Timing/Reports  ................................ ................................ ................................ ..... 43 
 Study Records Retention  ................................ ................................ ......................  43 
 Protocol Deviations  ................................ ................................ ...............................  43 
16 Publication Policy  44 
17 Literature References  46 
Appendix A: Schedule of Events  47 
Appendix B:  Toxicology Table  [ADDRESS_1111409] OF ABBREVIATION S 
AE Adverse Event/Adverse Experience  
BV Bacterial Vaginosis  
CFR Code of Federal Regulations  
CoC Certificate of Confidentiality  
CRF Case Report Form  
CROMS  Clinical Research Operations and Management Support  
CSR  Clinical Study Report  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH, 
DHHS  
DSMB  Data and Safety Monitoring Board  
eCRF  Electronic Case Report Form  
EIC Enrollment Informed Consent  
FDA Food and Drug Administration  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice   
GV Gardnerella Vaginalis  
HIPAA  Health Insurance Portability and Accountability Act  
IATA  International Air Transport Association  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmoni sation  
ICMJE  International Committee of Medical Journal Editors  
IDES  Emmes Corporation’s Internet Data Entry System  
IEC Independent or Institutional Ethics Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ITT Intent -to-Treat  
JAMA  Journal of the American Medical Association  
MedDRA Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
NAAT  Nucleic Acid Amplification Test  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
OCRA  Office of Clinical Research Affairs, DMID, NIAID, NIH, DHHS  
OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
viii ORA  Office of Regulatory Affairs, DMID, NIAID, NIH, DHHS  
PHI Protecte d Health Information  
PI [INVESTIGATOR_352349]-Protocol  
QA Quality Assurance  
QC Quality Control  
SAE Serious Adverse Event/Serious Adverse Experience  
SDCC  Statistical and Data Coordinating Center  
SI Site Investigator  
SIC Screening Informed Consent  
SOP  Standard Operating Procedure  
STD Sexually Transmitted Disease  
STI Sexually Transmitted Infection  
T. vaginalis  Trichomonas vaginalis  
ToC Test of Cure  
US [LOCATION_002]  
 
 
  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
ix PROTOCOL SUMMARY  
 
Title:  A Randomized, Double -Blind, Placebo Controlled, Phase 2  
Study to Assess Treatment of Gardnerella vaginalis Vaginal 
Colonization with Amoxicillin  
Phase:  II  
Population:  Approximately 245 healthy women  will be screened to enroll 
98 participants (to achieve 8 2 evaluable participants)  ages 18 -
45 with no evidence of vaginitis (yeast, trichomonas, bacterial 
vaginosis  (BV)) ; presence of Gardnerella vaginalis (GV) 
detected by [CONTACT_214347]; willing to use condoms during the study; 
not currently menstruating.  
Number of Sites:  Two US clinics:  University of Alabama at Birmingham and 
Wake Forest University  Health Sciences  
Study Durati on: Approximately  24 months is anticipated for enrol lment and 
completion of participation.  
Participation Duration:  It is anticipated that each participant will be part of the protocol 
for approximately 22 days ( screening visit, enrollment visit, 
and 1 fo llow-up visit ). 
Description of Agent or 
Intervention:  Amoxicillin 2 x 250 mg capsules PO bid 7 days  or placebo  
 
Objectives : 
 Primary:   To determine if treatment with amoxicillin eradicates 
GV in women who are colonized/infected with GV but have no 
clinical evidence of BV.  
Secondary:  
• To evaluate the safety and tolerability of amoxicillin 
compared to placebo.  
Exploratory:  
• To determine th e demographic and behavioral factors 
associated with vaginal colonization of GV ; 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
x  
Description of Study 
Design:  This is a randomized, double -blind, placebo -controlled Phase 
2 study .  It is anticipated that 245 women will be screened  in 
order to enroll 98 participants to achieve 82 evaluable 
participants.  Participants will be randomized to amoxicillin 2 x 
250 mg PO bid or placebo , for 7 day s.  Participation will 
include three visits in total – a Screening  Visit,  an Enrol lment  
Visit,  and 1 Follow - up visit.  Total participation for each 
woman will be approximately  22 days.   
Estimated Time to 
Complete Enrollment:  Approximately 24 months  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
xi Schematic of Study Design :  
Total N:  ~ 245 screened to enroll 98  (to achieve 82 evaluable)  
 
 
Study Visit 0:   
Screening  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Visit 1:  
Enrollment  
 
 
 
 
 
 
 
  
 
 
 
 
  
Enrollment :  review t ests results from Screening  Visit,  review eligibility,  obtain 
informed consent; collect interim sexual history, medical history, and concomitant 
medications  
Randomize  
Dispense study product and issue participant memory aid  
Remind all participants to abstain from vaginal intercourse or use a condom to prevent 
GV reinfection  N subjects - 
49 
Arm 1  N subjects - 
49 
Arm 2  
 Screening:  obtain informed consent; perform screening ; collect demographics, sexual 
history , medical history and concomitant medications;  
conduct clinical assessments and pregnancy test  
Samples Collected:   Urine for pregnancy testing; Vaginal swab specimen for test ing of 
yeast,  trichomonas and BV/abnormal vaginal flora and NAAT testing for T. vaginalis ; 
Vaginal swab specimen for testing of GV, BV, and future use  
 
 
 
 
NAAT for GV  
Negative  
 
End of study 
participation   
NAAT for GV  
Positive   
Vaginitis ( yeast, 
trichomonas, or 
BV/abnormal vaginal 
flora) Confirmed  
 
Ineligible:  End of 
study participation  No  
Vaginitis  
(yeast, trichomonas, or 
BV/abnormal vaginal flora ) 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
xii Study Visit 2:  
Follow -up (ToC) 
 
 
 
 
 
 
 
 
 
 
 
 Collect interim sexual history, medical history, and concomitant medications;  
assess AEs;  
conduct clinical assessment  
Samples Collected:  Vaginal swab specimen for testing of yeast,  trichomonas and 
BV/abnormal vaginal flora ; Vaginal swab specimen for testing of GV, BV, and future use  
 
 
 
Assessment of Final Study 
Outcome Measures  
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
1 1 KEY ROLES  
Individuals:   
 Principal Investigator  [INVESTIGATOR_651084] :   
Jane Schwebke, MD  
University of Alabama at Birmingham  
[ADDRESS_1111410] South  
Birmingham, AL [ZIP_CODE]   
Phone:  [PHONE_16791]  
Fax: [PHONE_16792]   
Email:  [EMAIL_9782]  
 
Site Investigator:  
Candice McNeil, MD, MPH  
Wake Forest University Health Sciences  
Medical Center Boulevard  
Winston -Salem, NC [ZIP_CODE]  
Phone:  [PHONE_16793]  
Fax:  [PHONE_16794]  
Email :  [EMAIL_15311]  
Institutions:  
 
NIH – Division of 
Microbiology and 
Infectious Diseases ,  
DMID   
  
 
 
Scientific Lead  
Carolyn Deal, PhD  
Medical Monitor   
Mohamed Elsafy , MD  
Clinical Project Manager    
Delmyra Turpin, RN, MPH, CCRP  
 
Pharmacist  
Binh Hoang, RPh, PharmaD, MBA  
 
  
DMID Protocol [ADDRESS_1111411]  
Noelle Myler , CCRA  
Research Assistant  
Mary Briggs  
 
  
UAMS STI CTG Statistical 
Consultant                         University of Arkansas for Medical Sciences  
Page C. Moore, Ph.D.  
 
 
 
 
 
 
  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
3 2 BACKGROUND INFORMATI ON AND SCIENTIFIC 
RATIONALE  
 Background Information  
Bacterial Vaginosis (BV) is the most common cause of vaginitis worldwide and is strongly 
associated with important public health issues including preterm birth and 
acquisition/transmission of HIV and other STDs (1, 2).  Although the exact cause of BV is 
unclear, the current epi[INVESTIGATOR_805067] y 
transmitted (3).  Further, there is mounting data to suggest that Gardnerella  vaginalis (GV) is the 
founder organism that is sexually transmitted (3).  Once GV is established, there is a resultant 
change in the vaginal microbiome characterized by [CONTACT_805076] c organisms leading to the syndrome of BV (3, 4).  GV is nearly univ ersally found in 
women with BV.  However, it may also be found in women who do not meet the current 
definition of BV, leading some to question its pathogenicity.  Others have hypothesized that 
there are strain differences among GV in terms of virulence fac tors(5). 
 Rationale  
If GV is necessary for the development of BV, then eradication of GV in women who do not 
meet the clinical criteria for BV should abort the future de velopment of BV.  Amoxicillin was 
chosen as the therapeutic intervention because it is highly active against GV but has limited 
efficacy against anaerobes associated with BV.  This Phase 2  study will determine if GV in the 
vaginal flora will be eradicated by [CONTACT_396293].  If amoxicillin successfully eradicates GV , we will 
develop the next step to examine prevention of BV through screening and treatment of GV.  
The amoxicillin  dose will  be 2 x 250 mg  capsules PO twice a day  for 7 days.   Placebo will be 
similarly packaged . 
Generally healthy women between ages 18 and 45 presenting to Health/STD clinics and 
responding to advertisements will be invited to participate in this study.  Women who are 
pregnant will not be permitted to enroll.  
  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
4 
 Potential Risks  and Benefits  
2.3.1  Potential Risks  
The primary  associated risk  with this study is a possible Adverse E vent, AE,  secondary to 
amoxicillin.  These could include allergic reaction, rash, nausea, vomiting , diarrhea  or other 
unforeseen events.   Amoxicillin may lead to penicillin allergy in the infant  of nursing mothers .  
Amoxicillin can reduce the effectiveness of hormonal contraceptives.  
Potential risks may include irritation from vaginal swabs or minor bleeding if the swabs are not 
used according to instructions.   Information concerning participants’ sexual history is necessarily 
detailed given the study’s objectives and may provoke some minor psychological or emotional 
stress when requested.  Participation in research may involve a loss of privacy.  Participant 
records will be kept as confidential as is possible under the law.  Individual identity will not be 
used in any reports or publications resulting from this study.  
There is no current standard of care for a positive GV test result  and women who test positive 
but do not have symptoms are usually not given any treatment .  Thus, if a participant’s GV test 
result remains positive after completion of the study, no further participant contact [CONTACT_805077].   
2.3.[ADDRESS_1111412] 
counseling, treatment, and referrals, as necessary. It has previously been observed that 
participants are empowered by [CONTACT_313356], for example, more about what BV is and how it can be 
prevented.    
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
5 3 OBJECTIVES  
 Study Objectives  
3.1.1  Primary objective:   
• To determine if treatment with amoxicillin eradicates GV in women who are 
colonized/infected with GV b ut have no clinical evidence of BV. 
3.1.2  Secondary objective:  
• To evaluate the safety and tolerability of amoxicillin compared to placebo.    
3.1.3  Exploratory objective:  
• To determine the demographic and behavioral factors associated with vaginal 
colonization of GV . 
 Study Outcome Measures  
3.2.1  Primary Outcome Measures  
• The proportion of participants with eradication of GV in each study arm at Visit 2 
(Day 15 -21) as assessed by [CONTACT_214347].  
3.2.2  Secondary Outcome Measures  
• The proportion of participants reporting related adverse events ( AEs and SAEs) in 
each study arm following the first dose of study product  through Visit 2 (Day 15-21). 
3.2.3  Exploratory Outcome Measures  
• The demographic and behavioral factors among women in the NAAT screening 
population without vaginitis who  are baseline GV po sitive and women who are 
baseline GV negative   
DMID Protocol [ADDRESS_1111413] of cure  (ToC) visit.  The study is designed to determine if 
amoxicillin will eradicate vaginal colonization/infection with GV when administered to women 
who are colonized/infected with GV but have no clinical evidence  of BV.  Women  who consent 
to screening participat ion will undergo pelvic examination on entry and vaginal specimens 
collected for pH, whiff test and wet prep microscopy  (Amsel criteria  with the exception of 
evaluation of vaginal discharge ), Nugent score , NAAT  for trich omonas ,  and quantitative NAAT 
for GV.  At Visit 1 (Enrol lment - Day 1) women who tested positive for GV by [CONTACT_214347], negative for 
BV by [CONTACT_805078] b y NAAT  will be enrolled and randomized to one of 
two groups  (amoxicill in or placebo).  A ToC will be completed at Visit 2 (Day 15-21).  
Baseline information will be collected from all women at the screening visit ( Visit 0 (Day -14 to -
7).  This information will consist of demographics, medical and sexual history , concomitant 
medications,  and clinical and laboratory findings.  Vaginal swabs will b e collected as noted 
above. Women who test positive for vaginitis at the  screening visit will be screen failures.  At the 
Enrol lment Visit (Visit 1, Day 1)  women who tested positive for  GV, negative for abnormal 
flora/ BV, and negative for trichomonas  will be enrolled and randomized.  Those who were 
negative for GV will be screen failures  and will not continue in the study, but , their, 
demographic, medical, and sexual history as well as b aseline swabs will be used for 
comparisons to the  GV positive women for an exploratory objective.  
Women who are enrolled will be asked to return for one further visit, Visit 2 (Day 15-21), where 
a ToC will be completed (a pelvic  exam  completed with the same specimens taken as  those at 
baseline with the exception of the trichomonas  NAAT ). 
Participants will be queried regarding any adverse outcomes and a ll AEs will be collected 
through Visit 2.  Safety oversight will be provided by [CONTACT_1629] I ndependent Safety Monitor (ISM) at 
each clinical site and by a Data Monitoring Safety Board (DSMB).  The DSMB members will 
meet at specified times during the course of the study as defined in the DSMB Charter.      
Laboratory testing will include nucleic aci d amplification test (NAAT) for trichomonas at each 
site’s local lab; Nugent score for BV at [CONTACT_805109]’s Lab ; quantitative NAAT for GV at 
LabCorp Research and Development Laboratory ; and assessment of vaginal pH, saline 
microscopy (yeast, trichomonas, clue cells)  at each site’s local lab . 
The duration of the study for participants who are enrolled and randomized will  be 
approximately [ADDRESS_1111414] screening 
follow up phone call .  It is expected that enrollment will be completed in approximately 12 
months.  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
7 Women will be asked to abstain from vaginal intercourse  or use condoms  at all times for vagina l 
intercourse  during their participation  independent of birth control use  or if pa rticipant is of non -
childbearing potential .  This restriction is to prevent participants from GV reinfection.   
For details on study procedures and evaluations and study schedule by [CONTACT_319650], see 
Sections 7, 8, and Appendix A: Schedule of Events . 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
8 5 STUDY ENROLLMENT AND  WITHDRAWAL  
Approximately  245 adult females ages 18-45, who are in good health, will be screened to enroll 
approximately 98 participants to achieve 8 2 evaluable participants.  No exemptions are granted 
on inclusion/exclusion criteria in DMID sponsored trials.  
Women will be recruited from Health/ STD clinics.   
Participants screened  who test positive for GV by [CONTACT_214347] , negative for BV by [CONTACT_515079]  (Nugent 
score 0 -3) and negative for trichomonas b y NAAT , will be  enrolled and randomized.   
Participants screened who test positive for vaginitis (i.e., yeast, trichomonas,  or BV/abnormal 
vaginal flora)  will be notified during the screening visit that they are not eligible to participate in 
the study.   
Participants screened who test negative for GV by [CONTACT_805079] a post screening 
visit telephone call that they are not eligible to participate in the study.   They will be counseled 
that asymptomatic GV does not require medical treatment and given instructions on relevant 
reasons to pursue medical care.  
 Participant  Inclusion Criteria  
 
Section [ADDRESS_1111415] meet all of the inclusion criteria : 
 
1. Women a ges 18 -45, inclusive ; 
2. No evidence of vaginitis (yeast, trichomonas,  and BV/abnormal vaginal flora ) or other  
vaginal conditions which in the opi[INVESTIGATOR_805068] *; 
 *These  causes will initially be detected by [CONTACT_805080] /abnormal vaginal 
flora confirmed by [CONTACT_805081]  (Nugent score  of 4-10) (see Section  8); 
3. Presence of GV detected by [CONTACT_214347] *; 
*results of NAAT testing will be available prior  to return for Enrollment visit;  
4. Willing to use condoms during vaginal intercourse while participating in the study ; 
5. Not currently menstruating  at screening visit ; 
6. Willing and able to provide written informed consent ; 
7. Negative urine pregnancy test  on all participants of childbearing potential  at study 
screening ;  
DMID Protocol [ADDRESS_1111416] be of non -childbearing potential* or must be using highly effective birth 
control** to avoid becoming pregnant.  
*Non -childbearing potential is defined as being post -menopausal for at least 1 
year, status after bilateral tubal ligation, or status after bilateral oophorectomy or 
status after hysterectomy.  
**In addition to the required use of condoms by [CONTACT_805082], p articipants must agree to avoid becoming pregnant by [CONTACT_805083] 30 days prior to screening  
and for the duration of the study ; 
• Intrauterine contraceptive device; OR  
• Oral contraceptives; OR  
• Hormonal injections; OR  
• Hormonal implants; OR  
• Contraceptive patches; OR  
• Monogamous relationship with vasectomized partner; OR  
• Exclusively same -sex relationships; OR  
• Abstinence;  
 
9. Participant is n ot planning on taking antibiotics or using an y intravaginal mi crobicide s 
from the Sc reening visit through the  Visit 2 Follow -up (ToC); 
10. Participant is willing and able to cooperate to the exten t and degree required b y this 
protocol at the discretion of the investigator.  
 
 Participant  Exclusion Criteria  
 
Participants eligible t o participate in this study must not meet any of the following exclusion 
criteria:  
1. Pregnant or nursing ; 
2. Allergic to penicillin , amoxicillin, cephalosporins, or other β-lactam antibiotic ; 
3. Use of antibiotics  in the past 14 days  prior to screening visit;   
4. HIV infected ;  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
10 5. Women taking immunosuppressive agents;  
6. History of renal impairment ; 
7. Use of an y investigational drug  within the past 30 days  prior to screening;  
8. Any other condition that, in the opi[INVESTIGATOR_871], would interfere with 
participation in the study.  
 Treatment Assignment Procedures  
Enrollment of participants will be done online using the enrollment module of AdvantageEDCSM.  
Participants  will be randomized using a 1: [ADDRESS_1111417] of randomized treatment 
assignments will be included in the enrollment module of The Emmes  Corporation’s Internet 
Data Entry System (IDES).  IDES will assign each enrolled participant  a blinded  treatment code 
from the list after demographi c and eligibility data have been entered into the system.   
Instructions for use of the enrollment module are included in the IDES User’s Guide.   
Each site will have a supply of blinded vials pre-labeled with treatment  numbers, each 
containing sufficient doses to treat a participant for seven days. Once a participant is assigned a 
treatment  number, the corresponding vial will be distributed to the participant . 
5.3.[ADDRESS_1111418] one dose of study drug will be conti nued in efficacy and 
safety follow -up, if the participant  agrees.  
Any enrolled participant  may withdraw or be withdrawn from the study for the following reasons:  
• The participant  withdraws consent  
• The study is terminated  
• For any reason that, in the opi[INVESTIGATOR_871], precludes the participant 's 
participation in the study  
• Participan t is lost to follow -up 
If a participan t withdraws or is withdrawn prior to completion of the study, the reason for this 
decision must be recorded in the case report forms  (CRFs). A participant who voluntarily 
withdraws from  the study  or has been discontinued from receiving further treatment will be 
encouraged to permit continued follow -up of AEs and to follow scheduled visits.  Participan ts 
should be asked to continue sche duled evaluations, complete an end -of-study evaluation, and 
be given appropriate care under medical supervision until the symptoms of any AE resolve or 
the participant ’s condition becomes stable.  
Refer to Section 7.[ADDRESS_1111419] to 
follow -up after signing the Enrollment Informed Consent ( EIC) form, r andomization, and receipt 
of study product will not be replaced.  Participants  who withdraw  consent  after signing the EIC 
form and randomization but before receipt of study product  may be replaced.  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
12 If withdrawal occurs after study treatment, the participant  will be asked to continue scheduled 
study procedures including safety and efficacy evaluations, if possible, and be given appropriate 
care under medical supervision if symptoms of any AE related to participation in the study are 
continuing. The participan t will be followed until the AE is resolved or until the participant’s 
condition becomes stable.  
Participants who request to withdraw their consent after study treatment from further 
participation in the study will be reminded of the importance of continui ng in the study for safety 
evaluations and will be encouraged to complete the Early Termination Visit  if they choose not to 
complete the remaining study visits. The Early Termination Visit procedures are listed in Section  
7.4. Participants  who choose to decline continuation in study participation will no longer be 
contact[CONTACT_51095] -up. 
In the case of participants  who fail to appear for a follow -up safety assessment, extensive effort 
(i.e., three documented contact [CONTACT_805084]/or e-mails, made on separate 
occasions) will be made to locate or recall them or at least to determine their health status.  
Participants  who cannot be located after extensive effort will no longer be contact[CONTACT_51095] -
up. These efforts will be documented in the participant ’s records.  
If a participant  is withdrawn from the study  due to an AE that prohibits continued partici pation in 
the study , she  will be given appropriate care and treatment under medical supervision until the 
condition has resolved or becomes stable.  
Safety and efficacy  data will be collected on any participant  who is withdrawn from the efficacy 
endpoint a nalysis . Refer to Section 11 for details on how participants  who are withdrawn will be 
handled during analysis.  
5.3.5  Termination of Study  
DMID reserves the right to terminate the study at any time for clinical or administrative reasons.   
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
13 6 STUDY INTERVENTION/I NVESTIGATIONAL PRODU CT 
 Study Product Description  
Amoxicillin, USP is a semisynthetic antibiotic, an analog of ampi[INVESTIGATOR_10312], with a broad spectrum of 
bactericidal act ivity against many gram -positive and gram -negative microorganisms.  Amoxicillin 
is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of 
active multiplication. It acts through the inhibition of cell wall biosynth esis that leads to the death 
of the bacteria.  
6.1.1  Acquisition  
The antibiotic  to be used in this study is FDA-approved for use in the US for gynecological and 
other infections. Amoxicillin 250 mg generic capsules and placebo will be purchased in bulk 
from the U AB Research Pharmacy.  
The research pharmacy will over -encapsulate the amoxicillin capsules for the active treatment 
arm and will create identical appearing placebo capsules containing lactose .  The UAB 
pharmacy will package the capsules (amoxicillin or placebo) into individual doses. This includes 
encapsulation, packaging, blinding and labeling according to the randomization schedule for 
each site  and applicable regulatory requirements . The UAB pharmacy will ship the medication to 
Fisher BioServices at the  following address:  
  
DMID Clinical  Materials Services  (CMS) Contract  
Fisher BioServices  
[ADDRESS_1111420]  
Germantown, MD [ZIP_CODE]  
Phone :  (240) 477 -1350  
Fax :  ([PHONE_16795]  
Email :  [EMAIL_5798]   
Study products  will be shipped from the DMID Clinical Materials Services  (CMS ) to the 
investigational site upon request and approval by [CONTACT_805085] . 
6.1.[ADDRESS_1111421] Storage and Stability  
All study medications are stable at room temperature  and will be stored at 20 -25°C/68-77°F . 
 Dosage, Preparation and Administration of Study 
Intervention/Investigational Product   
6.2.1  Dosage  
 
Participants will be randomized to one of two study products as follows:  
 
• Amoxicillin 2 x 250mg capsules PO twice a day for 7 days  
• Placebo [ADDRESS_1111422] under state and local rules and regulations.    
  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
15 6.2.3  Administration  
 
All active and placebo study products will be ora lly administered.  
 
Each participant will receive a single vial of medication.  Section 6.1.2  explains the packaging.  
Section 4 explains the design and study arms.  After randomization of the participant, the study 
clinician will obtain the next available dru g number and vial of medication  for that drug number.     
The participant  will be given instructions on how and when to take the medication and to bring 
the vial back to the clinic at the next follow -up visit. 
 
 Accountability Procedures for the Study 
Intervention/Investigational Product(s)  
Fisher will ship packaged study medication to the investigational sites.  At each site, study 
product will be kept in a locked storage cabinet at the clinic and administered by [CONTACT_71510].  A drug accountability log should be filled out for all st udy medications at the sites.   
After receipt of the study product , the site PI [INVESTIGATOR_805069]. The site PI [INVESTIGATOR_421220] a 
Site Research Pharmacist or an appropriately qualified staff member the responsibility for stud y 
product accountability.  The designee will be responsible for maintaining complete records and 
documentation of product receipt, accountability, dispensation, temperature and storage 
cond itions, and final disposi tion of study product. All study product, whether administered or not, 
must be documented on the appropriate study product accountabi lity record or dispensing log. 
The sponsor's monitoring staff will verify the participating clinic al sites’ study product 
accountability records and dispensing logs per the study monitoring plan.  
Unused dispensed study produc t returned to the site will be accounted for at the site and 
participant compliance will be recorded.   Any unused returned study product will be disposed of 
according to the site’s SOPs.   Upon completion or termination of the study and after the final 
monitoring visit, final disposition of the unused  never dispensed  study product  will be 
determined by [CONTACT_805086].  
 
 Assessment of Participant  Compliance with Study 
Intervention/Investigational Product  
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
16 Participants will be asked to bring the vial of medication and memory aid to the study personnel 
at their follow -up visit.  Study personnel will review adherence to the study medication schedule 
with the participants, including the participant’s memory aid , and record this on the appropriate 
data collection form  at Visit 2 ( ToC) and any Unscheduled Visits.   Study personnel will record 
the number of pi[INVESTIGATOR_114452].   The participant’s memory aid may be discarded by [CONTACT_805087].  
 Concomitant Medications/Treatments  
Administration of any medicat ions, therapi[INVESTIGATOR_014], or vaccines will be recorded on the appropriate 
data collection form. Concomitant medications will include all medications taken [ADDRESS_1111423] received study drug and are subsequently diagnosed with a concomitant 
infection that requires systemic antibiotics will receive treatment according to the local clinic’s 
standard protocols .  
At the discretion of the site PI, u se of new medication should prompt evaluation for  the presence 
of a new diagnosis of chronic medical disease or condition.  
Medications that might interfere  with the evaluation of the study product  should not be used 
unless absolutely necessary.  
Refer to Section 5 for medications that are prohibited for study eligibility and throughout study 
participation.  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
17 7 STUDY SCHEDULE  
Study visit information is listed in this section, Section 8 (Study Procedures/Evaluations ), and 
the Appendix A: Schedule of Events . Further instructions are described in the protocol -specific 
Manual of Procedures (MOP).  
 Visit 0 (Day -14 to -7) Screening  
• Potential participants will be provided with a description of the study (purpose and study 
procedures) and asked to read and sign the Screening I nformed Consent form , (SIC) . 
The SIC form will be  signed prior to performing any study eligibility procedures.  
• Eligibility criteria will be reviewed with participants .  
• Demographic information will be collected from the participant.  
• Sexual history for the past 90 days will be collected.   
• Medical history will be collected  only on active conditions within one  year prior to 
screening .  All concomitant medications taken in the last 14 days prior to the screening 
visit will be recorded on the appropriate data collection form . 
• A urine pregnancy test will be per formed on all participants of childbearing potential and 
must be negative prior to administration of study product.  
• A pelvic examination will be conducted for the collection of vaginal swab specimens for:  
pH, whiff test, and wet prep microscopy  (Amsel criteria  with the exception of 
evaluation of vaginal discharge ), Nugent score , NAAT  for trichomonas , quantitative 
NAAT for GV , and future use . If the on -site microscopy reveals a vaginal infection  (i.e., 
yeast, trichomonas, and  BV/abnormal vaginal flora) , the remaining specimens that 
were collected will be discarded  as the participant is not eligible for the study . For this 
study, vulvovaginal candidiasis will be defined by [CONTACT_805088]/or pseudohyphae ; trichomoniasis will be defined by  [CONTACT_805089] a positive NAAT for T. vaginalis ; abnormal flora /BV by 
[CONTACT_76478] 2/3 of the following criteria – pH >4.5, positive whiff test, ≥ 
20% clue cells.  These stricter criteria  will eliminate thos e women with intermediated 
flora as well as BV. We will not evaluate the presence of vaginal discharge per se due 
to the subjective nature of this observation. If these vaginal infections are found on the 
screening wet prep the participant will not be elig ible for the study.  
AFTER VISIT 0 ENDS AND PRIOR TO VISIT 1  
• Women who se tests from the s creening visit return  positive for GV by [CONTACT_214347], negative 
for abnormal flora/BV by [CONTACT_805090]  0-3 and negative for trichomon as by [CONTACT_805091] 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
18 will return for the E nrollment visit , which is scheduled at the end of the screening visit.  
• Women whose tests from the s creening visit return negative for GV by [CONTACT_805092] .  
• Women whose tests from the Screening visit retur n positive for GV by [CONTACT_805093].  
 Visit 1 (Day 1) Enrollment  
• Test results from the screening visit  will be  reviewed and the following actions 
complete d: 
• Participants whose tests from the s creening visit return positive for GV by [CONTACT_214347], 
negative for abnormal flora/BV by [CONTACT_515079] (Nugent score 0 -3) and negative for 
trichomonas by [CONTACT_214347], are considered eligible for study participation.  
• Study personnel will review study eligibility to ensure unchanged since the s creening 
visit.  Pregnancy test result from screening visit will be reviewed and confirmed to be 
negative.  
• Screened participants who are deemed eligible will be asked to read and  sign the 
Enrollment Informed Consent form, (EIC).  The EIC form will be signed prior to 
performing any study procedures.  
• Interim sexual history since the screening visit will be collected.  
• Medical history will be reviewed and updated as appropriate.  
• All concomitant medications taken since the screening visit  will be recorded on the 
appropriate data collection form . Previously recorded medications will be updated as 
appropriate . 
• Participants will then be enrolled and randomized to treatment vs. placebo (via 
Advantage EDC) and instructed to take the medication twice per day for 7 days.    
• Study personnel will schedule randomized participants to return for follow -up at Visit 2 
(Day 15-21). 
• Study drug, memory aid and instructions will be provided to participants prior to 
departure from clinic.   Remind participant to abstain from vaginal intercourse  or use 
condoms at  all times for vaginal intercourse until next visit independent of birth control 
use or if participant is of non -childbearing potential.  This restriction is to prevent 
participants from GV reinfection.     
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
19 
 Visit 2 (Day 15 [Window: Days 15 -21]) Follow -up (ToC) 
• Interim sexual history since the last clinic visit will be collected.  
• Medical histo ry will be reviewed and updated as appropriate.  
• All concomitant medications taken since Visit 1 will be recorded on the appropriate data 
collection form. Previously recorded medications will be updated as appropriate . 
• Compliance with the study protocol criteria will be assessed via review of pa rticipant  
memory aid , drug return, and review with pa rticipant . 
• Study personnel will discuss with participants and assess and record all AE/SAEs.  
• A pelvic examination will be conducted for the collection of vaginal swab specimens  as 
done  at screening , with the exception of trichomonas NAAT . 
• If the Visit [ADDRESS_1111424] is 
needed.    
 Early Termin ation Visit  
The following assessments will be performed at the early termination visit for participants  who 
withdraw, or are withdrawn or terminated from this study:  
• Interim sexual history since the last clinic visit will be collected.  
• Medical history will  be reviewed and updated as appropriate.  
• All concomitant medications taken since the last study visit  will be recorded on the 
appropriate data collection form . Previously recorded medications will be updated as 
appropriate . 
• Compliance with the study protocol criteria will be assessed via review of pa rticipant  
memory aid , drug return, and review with pa rticipant . 
• Study personnel will discuss  with participants and assess and  record all AE s/SAEs.  
Previously recorded AEs/SAEs will be updated as appropriat e. 
• If indicated for symptoms, a pelvic examination will be conducted for the collection of 
vaginal swab specimens for:  
• pH, whiff test, and wet prep to determine the etiology of current symptoms . 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
20 
 Unscheduled Visit  
Participants may be seen for unscheduled visits as necessary.  For example , for problems with 
the medication, development of intercurrent vaginal symptoms, or need for treatment of 
trichomonas.  
Any of the following activities may be conducted at the discretion of the site PI:  
• Interim sexual histo ry since the last clinic visit will be collected.  
• Medical history will be reviewed and updated as appropriate.  
• All concomitant medications taken since the last study visit  will be recorded on the 
appropriate data collection form . Previously recorded medications will be updated as 
appropriate . 
• Compliance with the study protocol criteria will be assessed via review of pa rticipant  
memory aid , drug return, and review with pa rticipant . 
• Study personnel will discuss  with participants and assess and  record all AE s/SAEs.  
Previously recorded AEs/SAEs will be updated as appropriate . 
• If indicated for symptoms, a pelvic examination will be conducted for the collection of 
vaginal swab specimens for:  
• pH, whiff test, and wet prep to determine the etiology of  current symptoms . 
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
21 8 STUDY PROCEDURES/EVA LUATIONS  
 Clinical Evaluations  
Medical history  only on  active conditions within one  year prior to screening  will be obtained by 
[CONTACT_805094] 0 and will be updated at each clinic visit. At the follow -up 
visits, an interim medical history will be obtained by [CONTACT_805095].  
Sexual history will be obtained by [CONTACT_805094] 0. Participants  will be 
queried at Vis it 1 and Visit 2 (and as needed at unscheduled and early termination visits) 
regarding sexual activity and condom use since the previous clinic visit.  
Medications history (concomitant medications) will include a review of all current medications 
and medica tions taken 14 days prior to the screening visit and  through study completion . This 
will occur at Visits 0, 1, and 2, and as needed at unscheduled and early termination visits . 
Prescription and over -the-counter drugs will be included (lubricants, intravaginal products, 
vitamins, herbs and supplements ). Assessment of eligibility will also include a review of all 
permitted and prohibited medications per the Participant  Inclusion and Exclusion Criteria (see 
Section  5.1). 
Study drug, memory aid and instructions will be provided to participants at Visit 1.  Compliance 
with the study drug will be assessed at Visit 2  (and as needed at unscheduled and ea rly 
termination visits)  via revi ew of participant memory aid, drug return, and review with participant.  
AE/SAE assessment will be reviewed with participants at Visit 2 (and as needed at unscheduled 
and early termination visits) and recorded.   
A pelvic examination  will be performed on Visit 0 and 2, and as indicated at unscheduled or 
early termination visits . All p elvic examinations will be performed by a qualified study clinician.    
Pelvic Exam ination : 
During pelvic exam ination , the following wi ll be used  for the clinical diagnosis of BV by [CONTACT_805096]. Instructions for obtaining and determining the presence of Amsel clinical criteria can be 
found in the protocol -specific MOP  and consist of the following:  
1) A fishy odor of the vaginal discharge with the addition of a drop of 10% KOH (positive 
whiff test );  
2) Clue cells ≥ 20% of the total vaginal squamous epi[INVESTIGATOR_651098] ; 
3) Vaginal fluid pH > 4.5.   
DMID Protocol [ADDRESS_1111425]. Schwebke’s lab.  
Quantitative NAAT  for GV will be performed at LabCorp Research and Development 
Laboratory.    
Bedside  Evaluation of Vaginitis  
A vaginal swab specimen should be used to determine the vaginal pH u sing ColorpHast pH 
paper.  Vaginal secretions should be placed into 0.[ADDRESS_1111426], trichomonas , and clue 
cells.  A drop of th e suspension would  be mixed with 10% KOH for the “whiff” test and KOH 
fungal prep.  
Nugent Criteria for Determination of BV:  
A vaginal swab for microbiologic assessment of BV by [CONTACT_805097]. The 
Nugent score utilizes a 0 -10 point scale for evaluation of vaginal flora an d is based on the 
weighted sum score of the following three bacterial morphotypes calculated from the slide exam 
under oil immersion (1000x):  
• Lactobacillus : Large Gram -negative rods  
• Gardnerella /Bacteroides  spp: thin, curved, Gram -variable rods  
• Mobiluncus  spp: thin, curved, Gram -variable rods  
The Nugent score is interpreted as follows: 0 -3 normal; 4 -6 intermediate; and 7 -10 BV. For the 
purposes of this study, a score > 3 is considered abnormal, and a score of 0 -3 is considered 
normal . 
NAAT testin g for T. vaginalis  
This is to be performed by [CONTACT_805098] . 
  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
23 8.2.2  Special Assays or Procedures  
The specific  details regarding the preparation of the samples collected for GV NAAT testing can 
be found in the protocol -specific MOP.  
8.2.3  Specimen  Preparation, Handling, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS]  Instructions for Specimen Preparation, Handling, and Storage  
Specimen preparation, handling, and storage will be done according to local clinic SOPs.  
Additional details can be found in the protocol -specific MOP .   
[IP_ADDRESS]  Specimen Shipment  
Gram stain specimen shipment for Nugent scoring to the UAB Central laboratory will be 
performed according to all applicable International Air Transport Association (ATA) 
requirements. The UAB Central laboratory address is as follows:  
UAB Infectious Diseases  Laboratory  
                                  [ADDRESS_1111427]  
                                  THT 220  
                                  Birmingham, AL [ZIP_CODE]  
Shipment of GV NAAT isolates to LabCorp  will be performed according to all applicable 
International Air Transport (IATA) requirements.  LabCorp address is as follows:  
                                  ATTN: Molecular R&D [ADDRESS_1111428]  
                                  Burlington, NC [ZIP_CODE]  
 
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
24 9 ASSESSMENT OF SAFETY  
 Specification of Safety Parameters  
Safety will be monitored throughout the study by a pelvic examination.  Safety will be assessed 
by [CONTACT_805099]:  
1. Serious adverse events occurring from the time of the study dose  through Visit 2. 
2. Non-serious adverse events occurring from the time of the study dose through Visit 2. 
 Methods and Timing for Assessing, Recording, and Analyzing 
Safety Parameters  
9.2.1  Adverse Events  
Adverse Event:    
ICH E6 defines an AE as any untoward medical occurrence in a patient or clinical investigation 
participant  administered a pharmaceutical product regardless of its causal relationship to the 
study treatment.  An AE can theref ore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of 
medicinal product.  The occurrence of an AE may come to the attention of study personnel 
during study visits an d interviews of a study recipi[INVESTIGATOR_12189], or upon 
review by a study monitor.  
All AEs including local and systemic reactions not meeting the criteria for “serious adverse 
events” should be captured on the appropriate CRF.  Information to be collected includes event 
description, time of onset, clinician’s  assessment of severity, relationship to study product 
(assessed only by [CONTACT_8703] a diagnosis, which would 
include MD, PA, Nurse Practitioner, DO, or  DDS), and time of resolution/stabilization of the 
event.  All AEs occurring while on study must be documented appropriately regardless of 
relationship.  All AEs will be followed to adequate resolution.  
Any medical condition that is present at the time th at the patient is screened should be 
considered as baseline and not reported as an AE.  However, if it deteriorates at any time 
during the study, it should be recorded as an AE.  
All AEs must be graded for severity and relationship to study product.  
DMID Protocol [ADDRESS_1111429] medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related.  
Severity of Event:   The following guidelines will be used to quantify intensity:  
Gastrointesti nal side effects which include nausea, vomiting, diarrhea, and abdominal pain will 
be assessed on a scale of 1 to 3 according to the toxicology table in Appendix B:  Toxicology 
Table  of this protocol.   
Systemic reactions which include allergic reaction, headache, fatigue, and myalgia will be 
assessed on a scale of 1 to 3 according to the toxicology table in Appendix B:  Toxicology Table  
of this protocol.   
All other  AEs will be graded using the following general criteria:  
Mild:  events require minimal or no treatment and do not interfere with the patient’s daily 
activities.  
Moderate :  events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
Severe :  events interrupt a patient’s usual daily activity and may require systemic drug therap y 
or other treatment. Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity.  Adverse events characterized as intermittent require 
docu mentation of onset and duration of each epi[INVESTIGATOR_1865].  
Relationship to Study Products:   The clinician’s assessment of an AE's relationship to study 
medication  is part of the documentation process, but it is not a factor in determining what is or is 
not reported in the study.   If there is any doubt as to whether a clinical observation is an AE, the 
event should be reported.  All AEs must have their relationship to study product assessed using 
the terms  “related” or “not related” .  In a clinical trial, the study pr oduct must always be suspect.  
To help assess, the following guidelines are used.  
• Related  – There is a reasonable possibility that the study product caused the adverse event. 
Reasonable possibility means that there is evid ence to suggest a causal relations hip 
between the study product and the adverse event.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the event . 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
26 9.2.2  Serious Adverse Events  
Serious Adverse Event (SAE) :  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the investigator or sponsor, it results in any of the following outcomes:  
• Death,  
• a life -threatening adverse event *,  
• inpatient hospi[INVESTIGATOR_29350],  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
• a congenital anomaly/birth defect.   
• Important medical events that may not result in death, be life -threate ning, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical 
judgment they may jeopardize the participant  and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Exampl es of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
* Life-threatening adverse event. An adverse event is considered “life -threatening” if, in the view 
of either the investigator or sponsor, its occurrence places the participant  at immediate risk of 
death.  It does not include an adverse event, had it occurred  in a more severe form, might have 
caused death.  
All SAEs will be:  
• recorded on the appropriate SAE  form and e CRF 
• followed through resolution by a study clinician  as defined in section 9.4 
• reviewed and evaluated by a study clinician  
9.2.3  Procedures to be Followed in the Event of Abnormal Clinical Findings  
The site PI [INVESTIGATOR_349793]/SAEs that are observed or rep orted during the 
study, regardless of their relationship to study product.  AEs/SAEs  or abnormal clinical findings 
will be documented, reported and followed appropriately.  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
27 
 Reporting Procedures  
 
The Protocol Chair will monitor all adverse events and report serious adverse events to DMID 
and each site’s local  IRB within [ADDRESS_1111430] be submitted immediately 
(within 24 hours of site awareness ) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
 
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_1111431]. Suite 650  
Bethesda, MD 2081 7, [LOCATION_003]  
SAE Hot Line: 1 -[PHONE_889] ( US) or 1 -[PHONE_1728] (outside US)  
SAE FAX Phone Number: 1 -[PHONE_1729] (US) or 1 -[PHONE_891] (outside US)  
SAE Email Address: [EMAIL_1393]  
 
Other supporting documentation of the event may be requested by [CONTACT_140159].  
 
The DMID medical monitor and clinical protocol manager will be notified of the SAE by [CONTACT_413656].  The DMID medical monitor will review and assess the SAE 
for regulatory reporting and potential impact on study participant safety and p rotocol conduct.  
 
At any time after completion of the study, if the investigator becomes aware of an SAE that is 
suspected to be related to study product, the investigator will report the event to the DMID 
Pharmacovigilance Group.   
9.3.[ADDRESS_1111432] with pregnant study participant s to obtain pregnancy outcome information. The 
pregnant participant  will be followed until delivery or until the end of pregnancy (in the case of 
miscarriage or pregnancy termination). Infants born to these study participant s will also be 
monitored for SAEs (congenital anomalies or other birth defects) and  other complicat ions for up 
to two  months after birth. Pregnancy reporting forms will be limited to collecting data on the 
following information:  
• prior maternal history including congenital abnormalities or pregnancy complications;  
• estimated date of conception;  
• estimated and actual date of delivery or end of pregnancy;  
• pregnancy outcome (live birth, stillbirth, miscarriage or elective termination);  
• mode of delivery;  
• maternal complications; and  
• neonatal complications (i.e., lethal or nonlethal congenital abnormality).  
Pregn ancies occurring in study participants  will be reported via AdvantageEDCSM on the 
Pregnancy Report form .   
 
 Type and Duration of Follow -up of Participants  after Adverse 
Events  
AEs and SAEs will be followed from the time of study treatment through resolutio n even if this 
extends beyond the study  reporting period, Visit 2. Resolution of an AE/SAE is defined as the 
return to pretreatment status or stabilization of the condition with the expectation that it will 
remain chronic.  
Follow -up procedures, evaluations, and outcomes will be recorded on the appropriate data 
collection form.  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
29 
 Halting Rules  
Further enrollment will be halted for DSMB  review/recommendation if any two participants 
experience an adverse event that is judged to be Severe (Grade 3) and  related to study product . 
DMID retains the authority to suspend additional enrollment and administration of study product 
during the entire study, as applicable . 
 Safety Oversight ( ISM plus DSMB)  
An Independent Safety Monitor (ISM) at each clinical researc h site will oversee the safety of 
research participants  at that site and will provide independent written evaluation of SAEs and 
related Grade [ADDRESS_1111433] of members with 
appropriate exper tise to contribute to the interpretation of the data from this trial.  
The DSMB will review study progress and participant, clinical,  and safety data at the following 
time points:  
• At specified times during the course of study as defined in the DSMB Charter,  
• Ad hoc when a halting rule is met, for immediate concerns regarding observations during 
the study, or as needed.  
• A final closeout meeting will be held at the end of the study after the database is locked 
and when the final study report is available.  
The DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organ izational meeting of the DSMB. As an outcome of each review/meeting, the DSMB will 
make a recommendation as to the advisability of proceeding with study administr ations (as 
applicable), and to continue, modify, or terminate the study.  The DSMB members will meet at 
specified times during the course of the study as defined in the DSMB Charter.  
DMID or the DSMB chair may convene the DSMB on an ad hoc basis according t o protocol 
criteria or if there are immediate concerns regarding observations during the course of the 
study. The DMID Medical Monitor is empowered to stop enrollment and study treatment if 
adverse events that meet the halting criteria are reported. The DM ID Medical Monitor will be 
DMID Protocol [ADDRESS_1111434] protections, study and laboratory procedures, study 
intervention administration, and data collectio n processes are of high quality and meet sponsor, 
ICH/GCP guidelines and applicable regulations ; and that the study is conducted in accordance 
with the protocol, protocol -specific manual of procedures  and applicable sponsor standard 
operating procedures.  Monitoring visits will include, but are not limited to, inspection of study 
facilities, review of regulatory files, accountability records, CRFs, IC forms , printouts of medical 
and laboratory reports  from the electronic medical records (EMR) system,  and pr otocol and 
GCP compliance.  Site monitors will have access to the study site, study personnel, and all 
study documentation  according to the DMID -approved site monitoring plan. Study monitors will 
meet with PIs to discuss any problems and actions to be take n and document visit findings and 
discussions.  
Site visits will be made at standard intervals as defined by [CONTACT_149098] . 
DMID Protocol [ADDRESS_1111435] compares the proportion 
of participants with eradication of GV in each study arm through Visit 2 (Day 15 -21) as assessed 
by [CONTACT_214347] .  
The null hyp othesis for the comparison is that there is no difference in proportions between 
study arms, with a two -sided alternative.  The test will be conducted using a Pearson Chi -Square 
test with Yates continuity correction  at the 5% two -sided  significance level. The hypothesis will 
be tested in the Intent -to-Treat ( ITT) efficacy analysis population for the primary analysis and 
repeated as a secondary analysis in the Per-Protocol ( PP) analysis population.  
 Sample Size Considerations  
Sample size calculations are base d on detecting a decrease in GV colonization  rate from 80% 
among participants receiving placebo to as large as 44% among participants receiving 
amoxicillin.  Using the two -sided Pearson Chi -Square test with Yates continuity correction, 
significance level o f 0.05, and assuming an amoxicillin to placebo allocation ratio of 1:1, 82 
women (41 in each arm) would provide 90% power to detect a difference in colonization rates of 
36% (i.e. 44% colonization  rate in the amoxicillin arm).  
Assuming a 15% drop -out rate  between enrollment and the ToC visit approximately 98 women 
will need to be randomized to obtain 82 women evaluable for the primary analysis.  Assuming 
40% of women without BV will have a positive NAAT test for GV at screening, approximately 
245 women wit hout BV will need to be screened to randomize 98 women in the study.  
 Planned Interim Analyses  
11.3.1  Safety Review  
The DSMB may review study progress and participant safety data at specified times  
during the course of study, as defined in the DSMB Charter. The study will be monitored to  
determine if any of the safety halting rules described above in Section 9.5 are met. The halting 
rules do not utilize any statistical cri teria and no formal hypothesis testing is planned to occur for 
the safety and enrollment data reviews  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
33 11.3.2  Efficacy Review  
There are no planned interim efficacy analyses for this study.  
 Final Analysis Plan  
A separate statistical analysis plan document will be g enerated that will contain the  details of the 
analyses. This section outlines the major components of the analyses.  
11.4.1   Analysis Populations  
Intent -to-Treat (ITT) Population:  This analysis population includes all randomized participants.  
The ITT population w ill be used as the primary efficacy analysis population.  
Safety Population:  This analysis population includes all randomized participants who received 
at least one dose of study treatment.  
Per-Protocol (PP) Population: This analysis population includes all  randomized participants 
who met all inclusion/exclusion criteria, are evaluable, adhered to the assigned study treatment 
regimen  (as defined below),  and returned to the study site for the ToC visit within the specified 
window (Visit 2 [Window: Day 15 -21]) and did not experience any of the following after 
enrollment:  
• Unprotected vaginal sexual intercourse between Visit 1 and Visit 2  
• New pregnancy reported by [CONTACT_423]  
• Receipt of any antibiotic or intravaginal microbicide  other than study drug  
Participants  are deemed evaluable if their BV and GV status can be determined at screening 
and their GV status can be determined at Visit 2.  Participan ts who are missing Gram stain, GV 
NAAT, or  Amsel results  at screening are not evaluable.  Participant s who are missing GV NAAT 
results at the Visit [ADDRESS_1111436]  80% of 
the scheduled doses (i.e. at leas t 12 of the 14 doses) of study treatment, as assessed by [CONTACT_788221][INVESTIGATOR_114452]. If pi[INVESTIGATOR_805070], participant  report will be used  to 
assess adherence .  
In the unlikely event of an error in randomization or study product administration, participants 
will be grouped by [CONTACT_805100].   
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
34 NAAT Screening Population:  This analysis population inclu des all screened women who are 
evaluated for GV by [CONTACT_214347].  
The NAAT screening population will be used as the exploratory efficacy analysis population.  
11.4.[ADDRESS_1111437] deviation, median, minimum, and maximum. For c ategorical variables, descriptive 
statistics will include counts and percentages per category.  
11.4.3  Safety Analysis Plan  
Safety evaluations will be based on the incidence, severity, and type of adverse events  and 
serious adverse events  as detailed in Section  9. Safety variables will be tabulated and 
presented for all participants in the Safety population, grouped by [CONTACT_3148].  
Unsolicited AEs will be coded by [CONTACT_61132]® for  preferred term and system organ class. The  
proportion of participants  and exact 95% confidence intervals of AEs will be computed in 
aggregate, as well as by  [CONTACT_61132]® categories. The number of SAEs will be reported by a 
detailed listing showing the type, Me dDRA® coding, relevant dates  (treatment dosing dates and 
AE onset and resolution dates), severity, relatedness, and outcome  for each even t. 
In addition to the descriptive analyses described above,  the proportion of participants who 
experience related adverse events in each study arm following the first dose of study product 
through Visit 2 (Day 15 -21) will be summarized overall and by [CONTACT_1570] .   In addition, the 
proportion of participants  who discontinue study product early due to adverse events  will be 
summarized overall and by [CONTACT_1570].  
11.4.4  Efficacy Analysis Plan  
[IP_ADDRESS]  Primary Efficacy Analysis  
For the primary analysis of the efficacy of amoxicillin in women who are infected with GV but 
have no clinical evidence of BV, t he number and proportion of women with eradication of GV at 
Visit 2 (Day 15 -21) will be summarized overall and by [CONTACT_39815] p.  The point estimates for 
the arm -specific proportions and  difference in proportions as well as corresponding 95% 
confidence intervals will be reported .  A test of hypothesis will be conducted using Pearson Chi -
Square test with Yates continuity correctio n at the 5% two -sided level of significance level  to 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
35 formally compare the treatment groups .  The primary analysis will be performed in the ITT 
analysis population and repeated as a secondary analysis in the PP analysis population.  
Eradication of GV is defi ned by a negative NAAT result for GV at Visit 2 (Day 15 -21).  
Participants who have a missing  GV NAAT result at the ToC visit are excluded from the PP 
analyses, and will be classified as treatment failures in the ITT analyses.  
[IP_ADDRESS]  Exploratory Efficacy Analysis  
Details of the exploratory efficacy analysis, as well as any additional exploratory analyses that 
may be performed to supplement the primary analysis, will be described in the separate 
Statistical Analysis Plan.  As an  example  of the latter, demographic an d baseline characteristics 
of participants  who received amoxicillin and were positive for BV by [CONTACT_805101] 2 (Day 15 -21) will be summarized.  
 
 
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
36 12 SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the 
protection of confidentiality of participants .  Each site will permit authorized representatives of the 
DMID, its designees, and appropriate regulatory agencies to examine (and when required by 
[CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits, and 
evaluation of the study safety and progress.  These repres entatives will be permitted access to 
all source data, which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, evaluation checklists, pharmacy dispensing records, recorded data 
from automated instru ments, copi[INVESTIGATOR_71975], microfiches, photographic negatives, microfilm or magnetic media, x -rays, and 
participant  files and records kept at the pharmacy, at the laboratories, and medico -technical 
departments involved in the clinical trial.  Data collection forms will be derived from  the eCRFs 
and be provided by [CONTACT_63662] (SDCC).  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
37 13 QUALITY CONTROL AND QUALITY ASSURANCE   
Following a written DMID -accepted site  quality management plan, the participating site s are 
responsible for conducting routine quality assurance (QA) and quality control (QC) activities to 
internally monitor study progress and protocol compliance. Each  site PI [INVESTIGATOR_805071]-related sites, source data/data collection forms, and reports for the purpose of 
monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_410966]. Each  
site PI [INVESTIGATOR_805072] a pplicable documentations 
are maintained on site.  
The SDCC will implement quality control procedures beginning with the data entry system and 
generate data quality control  checks th at will be run on the database.  Any missing data or data 
anomalies will be communicated to the site(s) for clarification and resolution.  
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
38 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
 Ethical Standard  
The site PI [INVESTIGATOR_805073] B elmont 
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research of 
the National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research (April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 an d 56, and ICH E6; 62 
Federal Regulation s [ZIP_CODE] (1997) ; and future revisions , if applicable. The site PI’s institution will 
hold a current Federal  Wide Assurance (FWA) issued by [CONTACT_92258] (OHRP) for federally funded research.  
 Institutional Review Board  
Prior to enrollment of participants  into this trial, the approved protocol and informed consent 
forms will be reviewed and approved by [CONTACT_140167].   A copy of the 
IRB letter of approval will be provided t o DMID.   
The IRB Federal  Wide Assurance number will be provided to DMID.  
Should amendments  to the protocol be required, the amendments will be written by [CONTACT_805102] [INVESTIGATOR_71467].  
 Informed Consent Process  
The site PI, or designated study staff, will choose participants in accordance with the eligibility 
criteria detailed in Section  5. Before any study procedures are performe d, participants must sign 
the S creening Informed Consent F orm and, if applicable  the Enrollment Informed Consent form 
that both compl y with the requirements of 21 CFR Part 50 and 45 CFR 46 and the local IRB.  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation.  There will be two consent 
forms : Screening Informed Consent (SIC) for the screening procedures (determination of 
eligibility confirmed  upon receipt of the GV results within [ADDRESS_1111438] specimen collection) 
and an Enrollment Informed Consent (EIC) for  the full study . Upon receipt of the GV test results 
and review of the original screening criteria, the  participant is confirmed to be el igible, they will 
then need to be consented using the EIC prior to continuation . 
Before any screening or study procedures are performed, participants will receive a 
comprehensive explanation of the proposed screening  procedures,  study procedures and study 
interventions/products, including the nature and risks of the trial, alternate therapi[INVESTIGATOR_014], any known 
AEs, the investigational status of the components, and the other elements that are part of 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
39 obtaining proper informed consent. Participants will also receive  a detailed explanation of the 
proposed use and disclosure of their protected health information  (PHI) , including specifically 
their specimens. Participants will be allowed sufficient time to consider participation  in the 
screening portion and  enrollment in the trial, after having the nature and risks of both the 
screening and  trial explained to them . Participants  will have the opportunity to discuss the trial 
with their family, friends, or legally authorized representative or think about it prior to agreei ng to 
participate.  
Both the SIC and EIC  will describe in detail the study interventions/products, study procedures, 
risks, and possible benefits given to participants. Neither informed consent form can include any 
exculpatory statements. Both informed cons ent forms will be IRB -approved, and participants will 
be asked to read and review the appropriate document. Upon reviewing the appropriate 
document, the site PI (or designee) will discuss the research study to participants and answer 
any questions that may  arise. Participants must sign the informed consent form (s), and written 
documentation of the informed consent process is required prior to starting any study 
procedures/interventions being done specifically for the trial, including administering study 
product.  
Study personnel may employ IRB -approved recruitment efforts prior to obtaining the 
participant’s consent; however, before any study procedures are performed to determine 
protocol eligibility, the SIC must be signed. Participants will be given a copy of all informed 
consent forms that they sign.  
By [CONTACT_805103] , participants agree to complete all evaluations required by [CONTACT_20767], 
unless the participant withdraws voluntarily or is terminated from the trial for any reason.  
The rights and welf are of participants will be protected by [CONTACT_805104].  
 Exclusion of Women, Minorities, and Children  (Special 
Populations)  
This trial will be inclusive of female adults who meet the Participant  Inclusion/Exclusion Criteria, 
regardless of religion  or ethnic background. Should the outcome of this trial be deemed 
acceptable, additional trials may be initiat ed in other populations .  
 Subject Confidentiality  
Subjects  will be identified by a participant number and not by [CONTACT_2300]. Subject  confidentiality is 
strictly held in trust by [CONTACT_421263], their study personnel, the sponsor, and their 
DMID Protocol [ADDRESS_1111439] party without prior written approval of the sponsor.  
All information provided by [CONTACT_941] s ponsor and all data and information generated by [CONTACT_122844] s as part of the tr ial (other than a participant ’s medical records) will be kept 
confidential by [CONTACT_7880] [INVESTIGATOR_421226].  This 
information and data will not be used by [CONTACT_7880] [INVESTIGATOR_805074] n conducting the trial. These restrictions do not apply to: (1) information that becomes 
publicly available through no fault of the site PI [INVESTIGATOR_29355]; (2) information that is 
necessary to disclose in confidence to an IRB solely for the evalu ation of the trial ; (3) 
information that is necessary to disclose in order to provide appropriate medical care to a study 
subject ; or (4) study results that may be published as described in Section  16. If a written 
contract for the conduct of the trial that includes confidentiality provisions inconsistent with this 
statement is executed, that contract’s confidentiality provisions shall apply rather than this 
statement.  
The study monitor, or other authorized representatives of the sponsor may inspect all 
docu ments and records required to be maintained by [CONTACT_7880]. This includes, but is not limited 
to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects  in this trial. 
The participating sites will permit access to such records.  
 
To protect privacy, we have received a Certificate of Confidentiality , CoC .  With this CoC, the 
participating sites  cannot be forced to release information that may identify the participant , even 
by a court subpoena, in any federal, state, or local civil, criminal, administrative, legislative, or 
other proceedings.  The participating sites  will use the CoC to resist any demands for 
information that would identify the participant , except as e xplained below.  
The CoC cannot be used to resist a demand for information from personnel of the [LOCATION_002] 
Government that is used for auditing or evaluation of federally funded projects, like this or local 
laws, such as for reporting of communicable di seases.  
A CoC does not prevent the partic ipant from voluntarily releasing information about themselves 
or their involvement in this research.  If any person or agency obtains a written consent to 
receive study  information, then the participating sites  may not use the CoC to withhold that 
information.   
The C oC does not prevent the participating sites  from reporting without the participant ’s 
consent, information that would identify the subject as a participant in the study  regarding 
DMID Protocol [ADDRESS_1111440] be lega lly reported including: child and elder abuse, sexual abuse, or wanting 
to harm themselves or others.  
 Study Discontinuation  
If the trial is discontinued, participants  who sign the EIC and are randomized and treated will 
continue to be fo llowed for safety assessments. No further study product will be administered . 
 Future Use of Stored Specimens  
Both the screening and enrolled subject populations will be consented to have vaginal swab 
samples stored for future vaginitis research .  Storage o f samples is optional and not a 
requirement for the study. If the participant consents to storage and future use of specimens, 
specimens will be kept at the UAB Central laboratory and LabCorp .  Participants will not be 
contact[CONTACT_805105] f uture research studies.  Future testing on specimens will 
only occur to the extent authorized in each study site’s SIC and EIC  or as otherwise authorized 
under applicable law and after review and approval by [CONTACT_805106] g the specimens.  
Archived specimens will be identified only by [CONTACT_805107].   
There will be no direct benefit to the participant from allowing the specim en to be stored and 
used for future purposes.  However, the results may provide information that will help in the 
diagnosis or treatment of future patients.  
The participant’s specimen will be kept until it is used up or destroyed.  It may be used to 
develo p new tests or products.  In some instances,  these may have potential commercial value .   
If a participant decides at any time that she does not want the specimen stored for future 
research she must contact [CONTACT_74309]/ doctor who will then notify the l aboratory/specimen 
archive.  The laboratory staff will then mark the specimens  by [CONTACT_1583] a “Destroy” label and they 
will be destroyed at the end of this study or removed from storage and destroyed.  
 
DMID Protocol [ADDRESS_1111441] and maintain data for each participant  enrolled in the study.  All source documents 
should be completed in a neat, legible manner to ensure accurate interpretation of data.  
Permanent ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014].  When making a change or 
correction, the origin al entry should be crossed out with a single line, and the change should be 
initialed and dated.  Do not erase, overwrite, or use correction fluid or tape on the original.  
Data reported in the eCRF should be consistent with the data collection form/source  documents 
or the discrepancies should be documented.   
The sponsor and/or its designee will provide guidance to investigators on making corrections to 
the data collection forms and eCRFs.  
 Data Management Responsibilities  
All data collection forms and laboratory reports must be reviewed by [CONTACT_307607], who will ensure that they are accurate and complete.  Adverse events must be 
graded, assessed for severity and causality, and reviewed by [CONTACT_7880] [INVESTIGATOR_1461].  Data 
collecti on is the responsibility of the clinical trial staff at the site under the supervision of the Site 
PI.  During the study, the investigator must maintain complete and accurate documentation for 
the study.  
The E mmes  Corporation will serve as SDCC for this st udy and will be responsible for data 
management, quality review, analysis, and reporting of the study data.  
 Data Capture Methods  
Clinical data (including AEs and concomitant medications) will be entered into a [ADDRESS_1111442] protection and internal quality checks, such as automatic range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate.  Clinical data will be entered 
directl y from the data collection forms/source documents.  
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
43 
 Types of Data  
Data for this study will include safety, laboratory, and outcome measures.  
 Timing/Reports  
 
Safety data will be provided to the DSMB and investigators as per the DSMB Charter.  
 Study Records R etention  
 
Records and documents pertaining to the conduct of this study, including data collection forms, 
source documents, consent forms, laboratory test results, and medication inventory records, must 
be retained by [CONTACT_114824] 2 years following the completion of this study.  No 
records may be destroyed without written permission from the sponsor.  
 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice 
(GCP), or Manual of Procedures re quirements.  The noncompliance may be either on the part of 
the participant , the investigator, or the study site staff.  As a result of deviations, corrective 
actions are to be developed by [CONTACT_3483].  
These practices are consistent  with ICH E6:  
4.[ADDRESS_1111443] be promptly reported to DMID, via the Emmes 
Corporation’s IDES . 
All deviations from the protocol must be addressed in study data collection forms.  A completed 
copy of the DMID approved Protocol Deviation (PD) Form must be maintained in the Regulatory 
File.  Protocol deviations must be submitted to the local IRB/IEC per th eir guidelines.  The site 
PI/study staff is responsible for knowing and adhering to their IRB requirements . 
DMID Protocol [ADDRESS_1111444] submitted for them to the National 
Library of Medicine’s PubMed Central ( http://www.ncbi.nlm.nih.gov/pmc/) an electronic version 
of their final, peer -reviewed manuscripts upon acceptance for publication, to be made publicly 
available no later than [ADDRESS_1111445] be accessible to the public on PubMed Central no later than 12 months 
after publication.  
 
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/  
• NIH Office of Extramural Research ( OER ) Grants an d Funding,  
http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_1111446] applied for certification of delayed posting.  
As part of the re sult posting a copy of this protocol (and its amendments) and a copy of the 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this trial, the responsible party is DMID which will register the trial and post results.  
 
Following completion of the study, the lead principal investigator  (PI) is expected to publish the 
results of this res earch in a scientific journal. The International Committee of Medical Journal 
Editors (ICMJE) member journals have adopted a trials -registration policy a s a condition for 
publication. This policy requires that all clinical trials be registered in a public trials registry such 
as ClinicalTrials.gov* (http://clinicaltrials.gov/), which is sponsored by [CONTACT_805108]. Other biomedical journa ls are considering adopting similar policies.  
 
The ICMJE defines a clinical trial as any research project that prospectively assigns human 
subjects  to intervention or comparison groups to study the cause -and-effect relationship 
between a medical inte rventi on and a health outcome. Studies designed for other purposes, 
such as to study pharmacokinetics  (PK) or major toxicity (e.g., Phase I trials), would be exempt 
from this policy.  
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
45 Results of any exploratory immunogenicity analysis will not be published prior  to publication of 
the primary immunogenicity results for this study.  
 
Refer to Public Law 110 -85, Section 801, Clinical Trial Databases.  
 
*Journal Citation:  
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration : a statement from the 
International Committee of Medical Journal Editors. N Engl J Med. 2004;351:1250 -1. 
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
46 17 LITERATURE REFERENCE S 
1. Hillier SL. The vaginal microbial ecosystem and resistance to HIV. AIDS research 
and human retroviruses. 1998;[ADDRESS_1111447] 1:S17 -21. 
2. Eschenbach DA. Bacterial vaginosis and anaerobes in obstetric -gynecologic 
infection. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America. 1993;[ADDRESS_1111448] 4:S282 -7. 
3. Schwebke JR, Mu zny CA, Josey WE. Role of Gardnerella vaginalis in the 
pathogenesis of bacterial vaginosis: a conceptual model. The Journal of infectious 
diseases. 2014;210(3):338 -43. 
4. Eschenbach DA, Hillier S, Critchlow C, Stevens C, DeRouen T, Holmes KK. 
Diagnosis and  clinical manifestations of bacterial vaginosis. American journal of 
obstetrics and gynecology. 1988;158(4):819 -28. 
5. Ahmed A, Earl J, Retchless A, Hillier SL, Rabe LK, Cherpes TL, et al. 
Comparative genomic analyses of 17 clinical isolates of Gardnerella  vaginalis provide 
evidence of multiple genetically isolated clades consistent with subspeciation into 
genovars. Journal of bacteriology. 2012;194(15):3922 -37. 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
47 APPENDIX A: SCHEDULE OF EVENT S 
 Screening  Enrollment  Follow -Up 
Unscheduled  
Early Termination  
Visit 0  
(Day -14 to -7) Visit 1  
(Day 1)  Visit 2  
(Day 15  
[Window: 15 -
21]) 
Signed Consent Form1 X X    
Assessment of Eligibility Criteria  X X    
Collection  of Demographics  X     
Review of Sexual History  X X X (X) X 
Review of Medical History2 X X X (X) X 
Review of Concomitant Medications  X X X (X) X 
Randomization   X    
Dispense memory aid and instructions   X    
Reminder on abstinence or condom 
use during vaginal intercourse to 
prevent GV reinfection   X    
Study Intervention   X    
Pelvic Examination  X  X (X) (X) 
Assessment of Adverse Events    X X X 
Assessment of study drug compliance  
(via review of memory aid and drug 
return)    X (X) (X) 
Clinical 
Laboratory  Urine Pregnancy Test  X     
Trichomonas , NAAT 
Test X     
pH, whiff test, and wet 
microscopy  (Amsel 
criteria)  X  X (X) (X) 
Research 
Laboratory  
 
 BV, Nugent score  X  X (X) (X) 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
48  Screening  Enrollment  Follow -Up 
Unscheduled  
Early Termination  
Visit 0  
(Day -14 to -7) Visit 1  
(Day 1)  Visit 2  
(Day 15  
[Window: 15 -
21]) 
Research 
Laboratory  Future Use3 X  X (X) (X) 
LabCorp  GV, quantitative 
NAAT  X  X (X) (X) 
 
 
(X) – As indicated/appropriate.  
1At Visit [ADDRESS_1111449] an extra swab specimen 
collected for future use .   
 
 
 
DMID Protocol 16 -0073 GV  Version 6.0 
 23 May 2019  
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
49 APPENDIX B:  TOXICOLOGY TABLE  
Gastrointestinal  Grade 1  Grade 2  Grade 3  
Nausea  No interference with 
activity  Some interference 
with activity  Prevents daily 
activities  
Vomiting  No interference with 
activity or 1 - 2 
epi[INVESTIGATOR_1841]/24 hours  Some interference 
with activity or > 2 
epi[INVESTIGATOR_1841]/24 hours  
 Prevents daily activity 
or requires  IV 
hydration  
Diarrhea  2 - 3 loose or watery 
stools or < 400 
gms/24 hours  4 - 5 loose or watery  
stools or 400 - 800 
gms/24 hours  6 or more loose or 
watery stools or > 
800gms/24 hours or 
requires IV hydration  
Abdominal Pain  Does not interfere 
with activity  Repeated use of non -
narcotic pain reliever 
> 24 hours or 
interferes with activity  Any use of n arcotic 
pain reliever or 
prevents daily activity  
Systemic Reactions  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Allergic Reaction  Pruritus without rash  Localized urticaria 
OR requires oral 
therapy  Generalized urticaria; 
angioedema OR 
anaphylaxis OR 
requires epi[INVESTIGATOR_805075] -
narcotic pain reliever 
>24 hours OR some 
interference with 
activity  Significant; any use 
of narcotic pain 
reliever OR prevents 
daily activity OR 
requires triptans  
Fatigue  No interference with 
activity  Some interference 
with activity  Significant; prevents 
daily activity  
Myalgia  No interference with 
activity  Some interference 
with activity  Significant; prevents 
daily activity  
 
 